Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses

J Control Release. 2007 Oct 8;122(3):345-8. doi: 10.1016/j.jconrel.2007.04.001. Epub 2007 Apr 6.


The products of biotechnology, recombinant proteins, monoclonal antibodies, antisense, RNA interference, or non-viral gene transfer, cannot be developed as pharmaceuticals for the brain, unless these molecules are re-formulated to enable transport across the blood-brain barrier (BBB). Large molecule drugs, and plasmid DNA, can be delivered across the BBB with receptor-specific molecular Trojan horses. Trojan horse BBB delivery systems, coupled with one of 3 different technology platforms (fusion proteins, avidin-biotin, or Trojan horse liposomes), can enable the BBB transport of virtually any large molecule drug or plasmid DNA.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / chemistry*
  • Binding Sites
  • Blood-Brain Barrier / metabolism*
  • DNA / administration & dosage*
  • DNA / pharmacokinetics
  • Drug Carriers / chemistry*
  • Humans
  • Liposomes
  • Recombinant Fusion Proteins / administration & dosage*
  • Recombinant Fusion Proteins / pharmacokinetics
  • Species Specificity


  • Antibodies, Monoclonal
  • Drug Carriers
  • Liposomes
  • Recombinant Fusion Proteins
  • DNA